布地奈德/福莫特罗粉吸入剂联合复方甲氧那明治疗急性呼吸综合征冠状病毒-2感染亚急性咳嗽的临床疗效分析  

Budesonide/Formoterol Fumarate Powder for Inhalation Combined with Compound Methoxyphenamine Clinical Efficacy Analysis of Subacute Cough in SARS-COV-2 Infection

作　　者：倪孔守[1] 费英明 王汝团 矫捷 NI Kongshou;FEI Yingming;WANG Rutuan;JIAO Jie(Department of Respiratory and Critical Care Medicine,Fuding Hospital,Fuding 355200,China)

机构地区：[1]福鼎市医院呼吸与危重症医学科,福鼎355200

出　　处：《福建医科大学学报》2024年第4期263-265,共3页Journal of Fujian Medical University

摘　　要：目的回顾性分析信必可都保[布地奈德/福莫特罗粉吸入剂(Ⅰ)=320μg/9.0μg]联合阿斯美(复方甲氧那明)治疗急性呼吸综合征冠状病毒-2(SARS-COV-2)感染后亚急性咳嗽的临床疗效。方法收集2022年12月—2023年6月确诊的SARS-COV-2(Omicron BA.5.2、BF.7感染)亚急性咳嗽患者220例,分为观察组和对照组,每组各110例。观察组给予信必可都保吸入(1吸/次,2次/日),阿斯美口服(2粒/次,3次/日);对照组给予咳必清、酮替芬和孟鲁司特钠三联药物常规止咳、平喘对症治疗。采用咳嗽程度评分表(CET)观察并记录治疗后第3、5、7天咳嗽缓解情况,检测呼出气一氧化氮(FeNO),并进行疗效评价。结果治疗后第3、5、7天患者的CET评分、FeNO值均较前下降。观察组临床控制86例,显效11例,有效9例,无效4例,总有效率96%;对照组临床控制68例,显效17例,有效13例,无效12例,总有效率89%。2组的总有效率比较,差别有统计学意义(P<0.05)。结论信必可都保和阿斯美联合治疗SARS-COV-2(Omicron BA.5.2、BF.7感染)亚急性咳嗽,可明显改善患者的咳嗽症状。Objective To retrospectively analyze the clinical efficacy of Xinbikedubao[budes-onide/formoterol fumarate powder for inhalation(I)=320μg/9.0μg]combined with compound me-thoxyphenamine(ASME)in the treatment of subacute cough after acute respiratory syndrome coronavirus-2(SARS-COV-2)infection.Methods 220 patients with subacute cough of SARS-COV-2(Omicron BA.5.2,BF.7 infection)diagnosed from December 2022 to June 2023 were collected,and divided into observation group and control group,110 cases in each group.In the observation group,the patients were treated with Xinbikedubao(1 inhalation/time,2 times/day)and ASME(2 capsules/time,3 times/day);in the control group,the patients were treated with three combinations of cough suppressants,keto-tifen and montelukast sodium.The cough evaluation test(CET)was used to observe and record the cough relief on the 3rd,5th and 7th days after treatment,and fractional exhaled nitric oxide(FeNO)was detected and evaluated for efficacy.Results Cough CET score and FeNO value detection of patients on the 3rd,5th and 7th days after treatment decreased compared with before.In the observation group,there were 86 cases of clinical control,11 cases of significant effect,9 cases of effective and 4 cases of inef-fective,with a total effective rate of 96%;in the control group,there were 68 cases of clinical control,17 cases of significant effect,13 cases of effective and 12 cases of ineffective,with a total effective rate of 89%.The difference in the total effective rate of the two groups was statistically significant when com-pared with each other(P<0.05).Conclusion The combination of Xinbikedubao and ASME for the treatment of subacute cough in SARS-COV-2(Omicron BA.5.2,BF.7 infection)significantly improved patients'cough symptoms.

关 键 词：布地奈德/福莫特罗粉吸入剂 复方甲氧那明 联合治疗 急性呼吸综合征冠状病毒-2 咳嗽 咳嗽程度评分表 

分 类 号：R511[医药卫生—内科学]